Key Highlights
- CoreWeave stock purchases totaled approximately $19.4M following a steep 19% share price decline post-Q4 earnings
- Kratos Defense & Security Solutions represented the largest single transaction at $23.2M
- Teradyne position trimmed by $12.9M, continuing a persistent selling pattern from ARK
- Rocket Lab holdings reduced despite strong quarterly results, as shares dropped around 5%
- Other notable transactions included Roku sales and new investments in Generate Biomedicines
Cathie Wood’s ARK Invest conducted a series of significant portfolio modifications on Thursday, February 27. The investment firm’s trading strategy showcased diverse sector exposure, with new positions and reductions across defense technology, cloud computing, and life sciences industries.
The headline transaction centered on Kratos Defense & Security Solutions, where ARK purchased 252,169 shares worth $23.2 million. This defense contractor focuses on unmanned systems and autonomous military technology, positioning itself squarely within ARK’s thematic focus on automation and advanced robotics.
Second on the buying list was CoreWeave, an artificial intelligence cloud computing provider. The firm acquired 198,980 shares representing roughly $19.4 million in value, split across its ARKK and ARKW fund portfolios.
CoreWeave, Inc. Class A Common Stock, CRWV
The CoreWeave purchase came amid significant market turbulence, with shares plummeting 19% during the trading session. This sharp decline followed the company’s fourth-quarter financial results, which showcased impressive revenue expansion but also highlighted widening losses and capital spending figures that surprised analysts.
ARK’s decision to accumulate shares during the selloff suggests the firm views the market’s negative response as an overreaction rather than a reflection of underlying business problems. The AI infrastructure market where CoreWeave competes has witnessed explosive growth in recent quarters.
Analyst sentiment toward CoreWeave remains constructive, with a Moderate Buy consensus rating. The stock has garnered eleven Buy recommendations alongside eight Hold ratings, with the average analyst price target of $114.18 implying roughly 43.5% upside potential from present levels.
Teradyne and Rocket Lab Face ARK Redemptions
On the selling side, ARK divested 38,773 shares of Teradyne worth $12.9 million spread across multiple exchange-traded funds. The company produces automated test equipment for semiconductors and industrial robotics solutions. This sale extends ARK’s ongoing trend of reducing its Teradyne allocation.
The firm also sold 46,921 shares of Rocket Lab totaling roughly $3.4 million. The aerospace manufacturer had just delivered quarterly financial results that exceeded analyst expectations for both earnings and revenue, though shares still fell approximately 5% on the day.
Rocket Lab reported solid launch activity and a growing backlog of customer contracts. However, the company pushed back the maiden voyage of its larger Neutron rocket to late 2026, which may have dampened investor enthusiasm.
Biotech and Tech Sectors See Further Portfolio Changes
ARK eliminated 46,389 shares of Roku representing $4.3 million from its flagship ARKK exchange-traded fund. The firm offered no public explanation for this particular divestment.
In the life sciences arena, ARK established a position in Generate Biomedicines with a purchase of 459,525 shares valued at $7.4 million through its genomics-focused ARKG fund. Concurrently, ARKG sold 39,423 shares of Ionis Pharmaceuticals worth $3.2 million.
Other position adjustments included selling 10,590 shares of Deere & Co for $6.6 million and trimming its Guardant Health stake by 27,334 shares valued at $2.7 million.
Smaller trades rounded out the day’s activity, including a 205,211 share reduction in PagerDuty worth $1.5 million and a 14,097 share purchase of Brera Holdings totaling approximately $15,600.
The combined CoreWeave and Kratos Defense purchases dominated ARK’s February 27 trading activity, accounting for more than $42 million in capital deployment across these two positions alone.
